Recombinant SARS-CoV-2 S-Trimer Fusion Protein (Omicron JN.1)  [MP108-100 or MP108-025] 

GenHunter is now offering 13 monoclonal antibodies against SARS-CoV-2 (Hu-1/WT, Beta, Delta, Omicron BA.1, Omicron BA.2, Omicron BA.2.76, Omicron BA.4, Omicron BA.5, Omicron XBB.1.5, Omicron EG.5, Omicron JN.1, and Human ACE2; more details below and in "Ordering" tab), 9 different SARS-CoV-2 antigens (Hu-1/WT, Beta, Delta, Omicron BA.1, Omicron BA.5, Omicron XBB.1.5, Omicron EG.5.1, Omicron JN.1, & Human ACE2), and 2 COVID-19 Neutralizing Antibody Rapid Test Kits (for the Omicron JN.1 or Omicron XBB.1.5 variants). 

SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), also known as COVID-19 coronavirus or 2019-nCoV, can infect human respiratory epithelial cells by interacting with the human ACE2 receptor. The spike protein is a large type I transmembrane protein composed of two subunits, S1 and S2. S1 primarily contains a receptor-binding domain (RBD) responsible for recognizing the cell surface receptor, while S2 includes the essential elements for membrane fusion. The S protein plays a crucial role in inducing antibody and T cell responses, as well as protective immunity. The main functions of the spike protein can be summarized as follows: mediating receptor binding and membrane fusion, defining the host range and viral specificity, serving as the primary target for neutralizing antibodies, being a critical target for vaccine design, and enabling transmission between different hosts through genetic recombination or mutations in the receptor-binding domain (RBD). References listed below.

SARS-CoV-2 Antibody & Antigen Products Available:

References:

1. Liang, J.G. et al (2021, February). S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nature Communications. 12:1346, 1-12. https://www.nature.com/articles/s41467-021-21634-1
2. Ma, J. et al (2021, June). Cryo-electron Microscopy Structure of S-Trimer, a Subunit Vaccine Candidate for COVID-19. Journal of Virology. 95:11, 1-14. https://journals.asm.org/doi/10.1128/jvi.00194-21
3. Richmond, P. et al (2021, February). Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. The Lancet. 397, 682-694. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00241-5/fulltext
4. Bravo, L. et al. (2022, January). Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. The Lancet. 399, 461-472. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00055-1/fulltext

All products are FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.